Novartis Ag (NVS) Capital Expenditures (2009 - 2026)

Novartis Ag has disclosed Capital Expenditures across 18 years of filings, most recently posting -$321.0 million for Q2 2026.

• In Q2 2026, Capital Expenditures rose 3.02% year-over-year to -$321.0 million; the TTM figure through Jun 2026 stood at -$1.6 billion (down 11.34% YoY), while the FY2025 annual figure was -$1.5 billion, down 13.32% from the prior year.
• Capital Expenditures came in at -$321.0 million for Q2 2026 at Novartis Ag, up from -$346.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of -$168.0 million in Q1 2023 to a low of -$609.0 million in Q4 2025.
• Average Capital Expenditures over 5 years is -$315.7 million, with a median of -$283.5 million recorded in 2022.
• Year-over-year, Capital Expenditures jumped 37.04% in 2022 and tumbled 37.44% in 2024.
• Over 5 years, Capital Expenditures stood at -$306.0 million in 2022, then slumped by 32.68% to -$406.0 million in 2023, then plunged by 37.44% to -$558.0 million in 2024, then slipped by 9.14% to -$609.0 million in 2025, then soared by 47.29% to -$321.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were -$321.0 million in Q2 2026, -$346.0 million in Q1 2026, and -$609.0 million in Q4 2025.